Please login to the form below

Not currently logged in
Email:
Password:

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

The Japanese company has plenty of other candidates in its emerging oncology pipeline, including HER2-targeting antibody-drug conjugate DS-8201 (trastuzumab deruxtecan), a rival to Roche’s Kadcyla in breast

Latest news

  • AZ’s bet on Daiichi’s rival to Kadcyla pays off AZ’s bet on Daiichi’s rival to Kadcyla pays off

    The two partners have reported top-line data from the pivotal phase 2 DESTINY-Breast01 study showing that DS-8201 (trastuzumab deruxtecan) met its primary objective in HER2-positive breast cancer ... patients who had failed or discontinued treatment with

  • Hemlibra off to a flyer as Roche raises 2019 forecasts Hemlibra off to a flyer as Roche raises 2019 forecasts

    There was some slippage for immunology drug MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) for breast cancer, with the declines seen most starkly in Europe where they fell 38% and 44% respectively.

  • AZ makes $6.9bn play for Daiichi Sankyo HER2 drug AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

    The $6.9bn deal, funded in part by an equity placement of approximately $3.5bn, includes a sizeable $1.35bn upfront payment which reflects the fact that the ADC – trastuzumab deruxtecan ... DS-8201 is currently in phase 3 testing for HER2-positive

  • Biosimilar Herceptin helps Roche gain new Perjeta recommendation Biosimilar Herceptin helps Roche gain new Perjeta recommendation

    intravenous trastuzumab are taken into consideration, the cost-effectiveness estimate is comfortably below £20, 000 per QALY gained.”. ... NICE already recommends Perjeta, given with trastuzumab and chemotherapy, for treating early HER2-positive

  • Roche submits Kadcyla for FDA Real-Time review Roche submits Kadcyla for FDA Real-Time review

    It combines two anti-cancer properties, trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1, which it licensed from biotech ImmunoGen.

More from news
Approximately 14 fully matching, plus 147 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...
Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....

Infographics